About: http://data.cimple.eu/news-article/89999b3b49ccc46618ae3372f27857022af925ad85dcac8f8f5dded9

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: http://data.cimple.eu/news-article/89999b3b49ccc46618ae3372f27857022af925ad85dcac8f8f5dded9 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

Attributes	Values
rdf:type	schema:NewsArticle
schema:articleBody	Scientists on Thursday described a drug which hijacks the body's appetite system as a potential "game changer" in treating obesity after research showed it could cut body weight by up to 20 percent. The results from the large-scale international trial, which were published in the New England Journal of Medicine, showed more than one third of those who took the drug semaglutide lost over one fifth of their body weight. The study, which involved almost 2,000 people in 16 countries, also showed three quarters of those who took the drug lost more than 10 percent of their bodyweight. The drug is currently used to treat diabetes and works by altering appetite regulation to reduce calorie intake. One of the main authors of the study, Rachel Batterham from University College London, called the study a "major breakthrough". "No other drug has come close to producing this level of weight loss -- this really is a game changer," Batterman said. "For the first time, people can achieve through drugs what was only possible through weight-loss surgery." Duane Mellor, a dietician from Aston Medical School in Birmingham, central England, told the BBC the drug "provided a useful option". But he cautioned that "weight loss will still need lifestyle change, and that any medication or change in lifestyle can bring potential risks and side-effects". The study's British authors highlighted the impact improved treatment of obesity could have on health outcomes for a range of illnesses, including Covid-19, heart disease, Type 2 diabetes and cancers. "This drug could have major implications for UK health policy for years to come," said Batterham. UK health experts have drawn a line between widespread obesity and the high death toll in the country during the Covid pandemic. With more than 114,000 deaths, Britain is among the worst-hit countries in Europe by the disease. The evidence from the trial has been submitted for the regulatory approval of semaglutide as a treatment for obesity in Britain, the European Union and the United States. csp/phz/tgb
schema:headline	Weight loss drug a 'game changer' in cutting obesity: study
schema:mentions	Calorie The Evidence (TV series) Type 2 diabetes Aircraft hijacking England national football team New England Hertz Birmingham Cardiovascular disease BBC News Obesity Weight loss European Union Pandemic Coronavirus disease United Kingdom United States Coronavirus disease 2019 Semaglutide Dietitian Aston Medical School Bariatric surgery Rachel McKenna University College London
schema:author	http://data.cimple.eu/organization/1f0054d541e000623a2c1e561a247c073ef6328e8be9ffafda7b3fcd
schema:datePublished	2021-02-11 (xsd:date)
http://data.cimple...sPoliticalLeaning	other political leaning
http://data.cimple...logy#hasSentiment	positive sentiment
http://data.cimple...readability_score	79 (xsd:integer)
http://data.cimple...tology#hasEmotion	happiness

Faceted Search & Find service v1.16.115 as of Oct 09 2023

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 5 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software